Key result
Combination therapy with cimetidine, a COX-2 inhibitor, and a RAS inhibitor (CCA therapy) resulted in partial remission lasting 12 to 31 months in three men with metastatic renal cell carcinoma.
Why the study?
Does combination therapy with cimetidine, a COX-2 inhibitor, and a RAS inhibitor induce remission in patients with metastatic renal cell carcinoma?
Case Report (n=3)
Does combination therapy with cimetidine, a COX-2 inhibitor, and a RAS inhibitor induce remission in patients with metastatic renal cell carcinoma?
Combination therapy with cimetidine, a COX-2 inhibitor, and a RAS inhibitor may offer an alternative treatment for metastatic RCC patients unfit for cytokine therapy.
Answers are grounded in this paper and cite their sources.
CCA therapy merits prospective evaluation in metastatic RCC; leaves open whether it induces durable remissions.
We report three cases of metastatic renal cell carcinoma (RCC) in which combination treatment of cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin system inhibitor (angiotensin converting enzyme inhibitor or angiotensin II type 1 receptor antagonist) (CCA therapy) was effective. Case 1: A 47-year-old man who had a 12-cm right renal tumor with multiple pulmonary and hepatic metastases refused cytokine therapy for economic reasons and received CCA therapy. All of the metastases showed partial remission, which continued for 12 months. Case 2: A 62-year-old man with multiple pulmonary and mediastinal lymph node metastases from clear cell RCC refractory to interferon-alpha and interleukin-2 started CCA therapy. Partial remission has been maintained for 16 months. Case 3: A 64-year-old man with pulmonary metastases from clear cell RCC discontinued interferon-alpha treatment due to its side effects after six months and received CCA therapy. Pulmonary metastases showed partial remission for 31 months. The CCA therapy could be an alternative treatment for metastatic RCC patients unfit for cytokine therapy.
No takes yet. Share an insight, caveat, or question.
Tatokoro et al. (2008) conducted a case report in Metastatic renal cell carcinoma (RCC) (n=3). CCA therapy (cimetidine, cyclooxygenase-2 inhibitor, and renin-angiotensin system inhibitor) was evaluated on Tumor response (partial remission). Combination therapy with cimetidine, a COX-2 inhibitor, and a RAS inhibitor (CCA therapy) resulted in partial remission lasting 12 to 31 months in three men with metastatic renal cell carcinoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: